Zolgensma (onasemnogene abeparvovec): risk for thrombotic microangiopathy

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Zolgensma
Active substance
onasemnogene abeparvovec
Procedure number
EMEA/H/C/004750/II/0008
Regulatory outcome
Variation
DHPC type
Type II variation
Human ATC code
M09AX09
Dissemination date
18/03/2021

How useful was this page?

Add your rating